Top

Diabetologia

Published in:

01-02-2005 | Article

The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes

Authors: S. M. Pöykkö, O. Ukkola, H. Kauma, E. Kellokoski, S. Hörkkö, Y. A. Kesäniemi

Published in: Diabetologia | Issue 2/2005

Abstract

Aims/hypothesis

Ghrelin is a natural growth hormone-releasing peptide thought to be involved in the regulation of energy metabolism. The recent studies concerning the association between ghrelin and insulin-like growth factor-I (IGF-I) concentrations have shown either negative correlation or no correlation at all. The aims of this study were to clarify the association between ghrelin and IGF-I concentrations in a large cohort and to characterize whether obesity, insulin resistance and type 2 diabetes affect this association.

Methods

We analysed fasting plasma ghrelin and IGF-I concentrations of 1,004 middle-aged subjects of the population-based OPERA study. Insulin resistance was estimated using QUICKI.

Results

IGF-I concentrations were negatively associated with ghrelin concentrations in the analysis of all subjects before (β=−0.32, p<0.001) and after adjustments for BMI, insulin levels, sex and age (β=−0.40, p<0.001). The association was particularly strong in males and in the higher BMI tertiles. The degree of association varied in relation to the glycaemic status: no insulin resistance: r ²=6.5% (p<0.001), insulin resistance without type 2 diabetes: r ²=21.0% (p<0.001), type 2 diabetes: r ²=25.4 (p<0.001). IGF-I levels explained larger proportion (r ²=9.8%) of the variation in ghrelin concentrations compared to fasting insulin concentration (r ²=3.0%) and BMI (r ²=1.5%).

Conclusions/interpretation

There is a negative and independent association between ghrelin and IGF-I concentrations in middle-aged subjects. The interaction between IGF-I and ghrelin is modified by obesity, IR and type 2 diabetes. Further studies are warranted to elucidate the role of ghrelin in the development of these states.

Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402:656–660CrossRef

Gnanapavan S, Kola B, Bustin SA et al. (2002) The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988–2991CrossRef

Wren AM, Small CJ, Ward HL et al. (2000) The novel hypothalamic peptide ghrelin stimulates food intake and growth hormone secretion. Endocrinology 141:4325–4328CrossRef

Shintani M, Ogawa Y, Ebihara K et al. (2001) Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway. Diabetes 50:227–232

Tschöp M, Smiley DL, Heiman ML (2000) Ghrelin induces adiposity in rodents. Nature 407:908–913CrossRef

Date Y, Nakazato M, Hashiguchi S et al. (2002) Ghrelin is present in pancreatic alpha-cells of humans and rats and stimulates insulin secretion. Diabetes 51:124–129

Nagaya N, Kojima M, Uematsu M et al. (2001) Hemodynamic and hormonal effects of human ghrelin in healthy volunteers. Am J Physiol Regul Integr Comp Physiol 280:R1483–R1487

Enomoto M, Nagaya N, Uematsu M et al. (2003) Cardiovascular and hormonal effects of subcutaneous administration of ghrelin, a novel growth hormone-releasing peptide, in healthy humans. Clin Sci (Lond) 105:431–435

Ukkola O, Pöykkö S (2002) Ghrelin, growth and obesity. Ann Med 34:102–108CrossRef

10.

Caixas A, Bashore C, Nash W, Pi-Sunyer F, Laferrere B (2002) Insulin, unlike food intake, does not suppress ghrelin in human subjects. J Clin Endocrinol Metab 87:1902CrossRef

11.

Nakagawa E, Nagaya N, Okumura H et al. (2002) Hyperglycaemia suppresses the secretion of ghrelin, a novel growth-hormone-releasing peptide: responses to the intravenous and oral administration of glucose. Clin Sci (Lond) 103:325–328

12.

Saad MF, Bernaba B, Hwu CM et al. (2002) Insulin regulates plasma ghrelin concentration. J Clin Endocrinol Metab 87:3997–4000CrossRef

13.

Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50:707–709

14.

Shiiya T, Nakazato M, Mizuta M et al. (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87:240–244CrossRef

15.

Pöykkö SM, Kellokoski E, Hörkkö S, Kauma H, Kesäniemi YA, Ukkola O (2003) Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 52:2546–2553

16.

Ikezaki A, Hosoda H, Ito K et al. (2002) Fasting plasma ghrelin levels are negatively correlated with insulin resistance and PAI-1, but not with leptin, in obese children and adolescents. Diabetes 51:3408–3411

17.

Arvat E, Di Vito L, Broglio F et al. (2000) Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans. J Endocrinol Invest 23:493–495

18.

Takaya K, Ariyasu H, Kanamoto N et al. (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85:4908–4911CrossRef

19.

Eden EB, Burman P, Holdstock C, Karlsson FA (2003) Effects of growth hormone (GH) on ghrelin, leptin, and adiponectin in GH-deficient patients. J Clin Endocrinol Metab 88:5193–5198CrossRef

20.

Meyer CW, Korthaus D, Jagla W et al. (2004) A novel missense mutation in the mouse growth hormone gene causes semidominant dwarfism, hyperghrelinemia, and obesity. Endocrinology 145:2531–2541CrossRef

21.

Koutkia P, Canavan B, Breu J, Johnson ML, Grinspoon SK (2004) Nocturnal ghrelin pulsatility and response to growth hormone secretogogues in healthy men. Am J Physiol Endocrinol Metab 287:E506–E512CrossRef

22.

Tannenbaum GS, Epelbaum J, Bowers CY (2003) Interrelationship between the novel peptide ghrelin and somatostatin/growth hormone-releasing hormone in regulation of pulsatile growth hormone secretion. Endocrinology 144:967–974CrossRef

23.

Wortley KE, Anderson KD, Garcia K et al. (2004) Genetic deletion of ghrelin does not decrease food intake but influences metabolic fuel preference. Proc Natl Acad Sci U S A 101:8227–8232CrossRef

24.

Tolle V, Kadem M, Bluet-Pajot MT et al. (2003) Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women. J Clin Endocrinol Metab 88:109–116CrossRef

25.

Schmidt A, Maier C, Schaller G et al. (2004) Acute Exercise has no effect on ghrelin plasma concentrations. Horm Metab Res 36:174–177CrossRef

26.

Murdolo G, Lucidi P, Di Loreto C et al. (2003) Circulating ghrelin levels of visceral obese men are not modified by a short-term treatment with very low doses of GH replacement. J Endocrinol Invest 26:244–249

27.

Whatmore AJ, Hall CM, Jones J, Westwood M, Clayton PE (2003) Ghrelin concentrations in healthy children and adolescents. Clin Endocrinol (Oxf) 59:649–654CrossRef

28.

Bellone S, Rapa A, Vivenza D et al. (2003) Circulating ghrelin levels in newborns are not associated to gender, body weight and hormonal parameters but depend on the type of delivery. J Endocrinol Invest 26:RC9–RC11

29.

Bellone S, Rapa A, Vivenza D et al. (2002) Circulating ghrelin levels as function of gender, pubertal status and adiposity in childhood. J Endocrinol Invest 25:RC13–RC15

30.

Kitamura S, Yokota I, Hosoda H et al. (2003) Ghrelin concentration in cord and neonatal blood: relation to fetal growth and energy balance. J Clin Endocrinol Metab 88:5473–5477CrossRef

31.

Dall R, Kanaley J, Hansen TK et al. (2002) Plasma ghrelin levels during exercise in healthy subjects and in growth hormone-deficient patients. Eur J Endocrinol 147:65–70CrossRef

32.

Malik IA, English PJ, Ghatei MA, Bloom SR, MacFarlane IA, Wilding JP (2004) The relationship of ghrelin to biochemical and anthropometric markers of adult growth hormone deficiency. Clin Endocrinol (Oxf) 60:137–141CrossRef

33.

Rigamonti AE, Pincelli AI, Corra B et al. (2002) Plasma ghrelin concentrations in elderly subjects: comparison with anorexic and obese patients. J Endocrinol 175:R1–R5CrossRef

34.

Jones JI, Clemmons DR (1995) Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 16:3–34CrossRefPubMed

35.

Rantala AO, Kauma H, Lilja M, Savolainen MJ, Reunanen A, Kesäniemi YA (1999) Prevalence of the metabolic syndrome in drug-treated hypertensive patients and control subjects. J Intern Med 245:163–174CrossRef

36.

Katz A, Nambi SS, Mather K et al. (2000) Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 85:2402–2410CrossRefPubMed

37.

Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE, Weigle DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50:1714–1719

38.

Gröschl M, Wagner R, Dotsch J, Rascher W, Rauh M (2002) Preanalytical influences on the measurement of ghrelin. Clin Chem 48:1114–1116

39.

Pombo M, Pombo CM, Garcia A et al. (2001) Hormonal control of growth hormone secretion. Horm Res 55(Suppl 1):11–16CrossRef

40.

Veldhuis JD, Bowers CY (2003) Three-peptide control of pulsatile and entropic feedback-sensitive modes of growth hormone secretion: modulation by estrogen and aromatizable androgen. J Pediatr Endocrinol Metab 16(Suppl 3):587–605

41.

Janssen JA, van der Toorn FM, Hofland LJ et al. (2001) Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy. Eur J Endocrinol 145:711–716CrossRef

42.

Hoybye C, Barkeling B, Espelund U, Petersson M, Thoren M (2003) Peptides associated with hyperphagia in adults with Prader–Willi syndrome before and during GH treatment. Growth Horm IGF Res 13:322–327CrossRef

43.

Tolle V, Bassant MH, Zizzari P et al. (2002) Ultradian rhythmicity of ghrelin secretion in relation with GH, feeding behavior, and sleep–wake patterns in rats. Endocrinology 143:1353–1361CrossRef

44.

Aimaretti G, Corneli G, Baldelli R et al. (2003) Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. Clin Endocrinol (Oxf) 59:56–61CrossRef

45.

Clemmons DR (2001) Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 55(Suppl 2):73–79CrossRef

46.

Tacke F, Brabant G, Kruck E et al. (2003) Ghrelin in chronic liver disease. J Hepatol 38:447–454CrossRef

47.

Le Roith D (1997) Seminars in medicine of the Beth Israel Deaconess Medical Center. Insulin-like growth factors. N Engl J Med 336:633–640CrossRefPubMed

48.

Janssen JA, Lamberts SW (2002) The role of IGF-I in the development of cardiovascular disease in type 2 diabetes mellitus: is prevention possible? Eur J Endocrinol 146:467–477CrossRef

49.

Le Roith D, Scavo L, Butler A (2001) What is the role of circulating IGF-I? Trends Endocrinol Metab 12:48–52CrossRef

50.

Ukkola O (2003) Ghrelin and insulin metabolism. Eur J Clin Invest 33:183–185CrossRef

51.

Broglio F, Benso A, Castiglioni C et al. (2003) The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab 88:1537–1542CrossRef

52.

Barkan AL, Dimaraki EV, Jessup SK, Symons KV, Ermolenko M, Jaffe CA (2003) Ghrelin secretion in humans is sexually dimorphic, suppressed by somatostatin, and not affected by the ambient growth hormone levels. J Clin Endocrinol Metab 88:2180–2184CrossRef

53.

Shuto Y, Shibasaki T, Otagiri A et al. (2002) Hypothalamic growth hormone secretagogue receptor regulates growth hormone secretion, feeding, and adiposity. J Clin Invest 109:1429–1436CrossRef

54.

Liu YL, Yakar S, Otero-Corchon V, Low MJ, Liu JL (2002) Ghrelin gene expression is age-dependent and influenced by gender and the level of circulating IGF-I. Mol Cell Endocrinol 189:97–103CrossRef

55.

Baldanzi G, Filigheddu N, Cutrupi S et al. (2002) Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol 159:1029–1039CrossRef

56.

Hosoda H, Doi K, Nagaya N et al. (2004) Optimum collection and storage conditions for ghrelin measurements: octanoyl modification of ghrelin is rapidly hydrolyzed to desacyl ghrelin in blood samples. Clin Chem 50:1077–1080CrossRef

57.

Marzullo P, Verti B, Savia G et al. (2004) The relationship between active ghrelin levels and human obesity involves alterations in resting energy expenditure. J Clin Endocrinol Metab 89:936–939CrossRef

58.

Ariyasu H, Takaya K, Hosoda H et al. (2002) Delayed short-term secretory regulation of ghrelin in obese animals: evidenced by a specific RIA for the active form of ghrelin. Endocrinology 143:3341–3350CrossRef

Title: The negative association between plasma ghrelin and IGF-I is modified by obesity, insulin resistance and type 2 diabetes
Authors: S. M. Pöykkö
O. Ukkola
H. Kauma
E. Kellokoski
S. Hörkkö
Y. A. Kesäniemi
Publication date: 01-02-2005
Publisher: Springer-Verlag
Published in: Diabetologia / Issue 2/2005
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-004-1635-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Aims/hypothesis

Methods

Results

Conclusions/interpretation

Please log in to get access to this content

Other articles of this Issue 2/2005

Genetic testing for maturity onset diabetes of the young: uptake, attitudes and comparison with hereditary non-polyposis colorectal cancer

High titres of IgA antibodies to enterovirus in fulminant type-1 diabetes

Prevalence of obesity, glucose homeostasis disorders and metabolic syndrome in psychiatric patients taking typical or atypical antipsychotic drugs: a cross-sectional study

Use of a reference four-component model to define the effects of insulin treatment on body composition in type 2 diabetes: the ‘Darwin study’

Glycation of low-density lipoproteins by methylglyoxal and glycolaldehyde gives rise to the in vitro formation of lipid-laden cells

Orosomucoid in urine is a powerful predictor of cardiovascular mortality in normoalbuminuric patients with type 2 diabetes at five years of follow-up

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials